Embodied Intelligence + Drug Discovery = ? C12.ai Unveils Industry's First Pharmaceutical R&D Intelligent Robot | Yunqi Capital
Accelerating Drug Discovery and Development
In the AI era, embodied intelligence — with generalization as its core strength — is expanding what robots can do.
Recently, C12.ai, a Yunqi Capital angel-round portfolio company, unveiled LabBot, the industry's first intelligent robot for pharmaceutical R&D. Trained independently by C12.ai on multi-source, multi-modal data from the drug discovery field, LabBot can autonomously design and execute experiments, analyze results, and continuously learn from expert feedback and experimental outcomes. It aims to break traditional lab workflows' dependency on human personnel, pushing laboratories from automation toward true intelligence and accelerating new drug development and time-to-market.
In this edition of "Yunqi Capital," we take a closer look at LabBot and how embodied intelligence is transforming pharmaceutical research.
► Yunqi Capital's Perspective
Yunqi Capital has been deeply involved in AI and robotics for many years. We believe that traditional pharmaceutical R&D relies heavily on both knowledge-intensive and physical-operation tasks, which significantly constrains the drug discovery process. C12.ai切入 the problem at the most central link in the lab, creatively combining LLMs with embodied intelligence to address efficiency and cost bottlenecks and drive innovation in drug development.
On the LLM front, C12.ai integrates carefully fine-tuned vertical models with large foundation models, enabling a closed loop of automated experiment design, simulated execution, and data feedback. On the embodied intelligence front, the C12 team has extensively optimized the robot's perception, locomotion, and manipulation capabilities for laboratory scenarios, advancing the practical deployment of embodied AI in specific settings.
We look forward to seeing the C12.ai team leverage its cutting-edge AI capabilities in drug discovery, agile hardware optimization expertise, and solid engineering experience to achieve applied innovation in embodied intelligence for the vertical scenario of pharmaceutical R&D.
01
Advancing Drug Discovery: From Automation to Intelligence
C12.ai developed LabBot with a clear mission: use advanced AI and embodied intelligence to solve the efficiency and cost bottlenecks in pharmaceutical R&D, handing tedious and repetitive tasks over to intelligent robots so that scientists can focus on creative work — ultimately pushing drug discovery toward greater efficiency.
LabBot's brain is a specialized AI agent. Presented with a molecular structure, it can rapidly design multiple highly feasible synthesis routes and recommend the optimal one, then develop a detailed experimental plan based on the selected route. Whether during reactions or after experiments are complete, LabBot can quickly and accurately interpret various spectroscopic data, including LC-MS, helping researchers deeply understand results and verify reaction success.
LabBot can also identify potential hazards in experiments and formulate contingency plans, ensuring operational safety. Moreover, it continuously learns and improves from expert feedback and experimental data, becoming progressively more intelligent and efficient.
02
Eyes, Legs, and Hands Working Together: Optimized Perception, Locomotion, and Manipulation
LabBot's perception, locomotion, and manipulation capabilities are powered by its "eyes" (RGB-D cameras), "legs" (a laser-navigated mobile base), and dual "hands" (high-precision force-controlled robotic arms).
- Perception: LabBot's RGB-D cameras capture and analyze lab conditions in real time, providing precise 3D visual data that enables accurate identification and localization of various objects and equipment.
- Locomotion: The laser-navigated mobile base allows LabBot to autonomously plan paths, move freely around the laboratory, avoid obstacles, and reach designated workstations.
- Manipulation: LabBot's high-precision force-controlled robotic arms deliver exceptional operational capability. They can precisely grasp, place, rotate, and manipulate equipment ranging from test tubes and beakers to complex apparatus. The force control function ensures safety and accuracy during delicate operations.
03
The People Behind LabBot
Behind LabBot is C12.ai's founding team with combined expertise across AI, robotics, and pharmaceutical R&D.
C12.ai is led by recognized figures in AI and pharmaceutical research. Founder Zhigang Chen previously served as Chief Digital Officer at WuXi AppTec, head of Tencent's medical big data lab, and chief architect at Alibaba Health, with years of deep experience at the intersection of healthcare, pharmaceuticals, and AI. Team members hail from the University of Michigan, MIT, National University of Singapore, Peking University, Zhejiang University, and Nanjing University — a multidisciplinary group of engineers, chemists, computer scientists, and data scientists with cross-industry DNA. The team has accumulated extensive experience in laboratory digitalization and efficient collaborative operations, bringing interdisciplinary perspectives and innovative thinking to deliver more efficient solutions for scientists and enterprises in R&D practice.
AI has ushered in the era of embodied intelligence for robotics. Yunqi Capital looks forward to working with more innovative forces to unlock further possibilities for embodied intelligence applications.
